Personensuche
Personensuche
Es wurde 1 Person gefunden.
Klinik und Poliklinik für Urologie am Universitätsklinikum Essen
Anschrift
Hufelandstraße 55
45122 Essen
45122 Essen
Telefon
E-Mail
Funktionen
-
Direktor, Klinik für Urologie
Aktuelle Veranstaltungen
-
2024 WS
Vergangene Veranstaltungen (max. 10)
-
2024 SS
-
2023 WS
-
2023 SS
-
2022 WS
-
2022 SS
Die folgenden Publikationen sind in der Online-Universitätsbibliographie der Universität Duisburg-Essen verzeichnet. Weitere Informationen finden Sie gegebenenfalls auch auf den persönlichen Webseiten der Person.
-
Activity of Lutetium-177 Prostate-specific Membrane Antigen and Determinants of Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Cabazitaxel: The PACAP StudyIn: European Urology Oncology Jg. 7 (2024) Nr. 5, S. 1132 - 1140Online Volltext: dx.doi.org/
-
Bricker versus Wallace ureteroileal anastomosis : A multi-institutional propensity score-matched analysisIn: International Journal of Urology Jg. 31 (2024) Nr. 7, S. 813 - 818Online Volltext: dx.doi.org/
-
Combining PSMA-PET and PROMISE to re-define disease stage and risk in patients with prostate cancer : A multicentre retrospective studyIn: The Lancet Oncology Jg. 25 (2024) Nr. 9, S. 1188 - 1201Online Volltext: dx.doi.org/ (Open Access)
-
Detection of tumour heterogeneity in patients with advanced, metastatic castration-resistant prostate cancer on [⁶⁸Ga]Ga-/[¹⁸F]F-PSMA-11/-1007, [⁶⁸Ga]Ga-FAPI-46 and 2-[¹⁸F]FDG PET/CT : a pilot studyIn: European Journal of Nuclear Medicine and Molecular Imaging (2024) in pressOnline Volltext: dx.doi.org/ (Open Access)
-
Diagnostic Accuracy of ⁶⁸Ga-FAPI Versus ¹⁸F-FDG PET in Patients with Various MalignanciesIn: Journal of Nuclear Medicine (JNM) Jg. 65 (2024) Nr. 3, S. 372 - 378Online Volltext: dx.doi.org/ (Open Access)
-
Differences and Common Ground in ¹⁷⁷Lu-PSMA Radioligand Therapy Practice Patterns : International Survey of 95 Theranostic CentersIn: Journal of Nuclear Medicine (JNM) Jg. 65 (2024) Nr. 3, S. 438 - 445Online Volltext: dx.doi.org/ (Open Access)
-
Enhancing risk stratification models in localized prostate cancer by novel validated tissue biomarkersIn: Prostate Cancer and Prostatic Diseases (2024) in pressOnline Volltext: dx.doi.org/ (Open Access)
-
Establishing Medical Intelligence - Leveraging Fast Healthcare Interoperability Resources to Improve Clinical Management : Retrospective Cohort and Clinical Implementation StudyIn: Journal of Medical Internet Research (JMIR) Jg. 26 (2024) e55148Online Volltext: dx.doi.org/ (Open Access)
-
Harninkontinenz nach radikaler Prostatektomie beim Prostatakarzinom : Aktuelle Daten von 17.149 Patienten aus 125 zertifizierten ZentrenIn: Die Urologie Jg. 63 (2024) Nr. 1, S. 67 - 74Online Volltext: dx.doi.org/
-
Head-to-head comparison of ⁶⁸ Ga-FAPI-46 PET/CT, ¹⁸F-FDG PET/CT, and contrast-enhanced CT for the detection of various tumorsIn: Annals of Nuclear Medicine (2024) in pressOnline Volltext: dx.doi.org/
-
Kick-Starting Molecular Theranostics in Renal Cell CarcinomaIn: Journal of Nuclear Medicine (JNM) Jg. 65 (2024) Nr. 5, S. 744 - 745Online Volltext: dx.doi.org/ (Open Access)
-
Magnetic Resonance Imaging-guided Active Surveillance Without Annual Rebiopsy in Patients with Grade Group 1 or 2 Prostate Cancer : The Prospective PROMM-AS StudyIn: European Urology Open Science Jg. 59 (2024) S. 30 - 38Online Volltext: dx.doi.org/ (Open Access)
-
Mortality from prostate cancer in the years 2007–2021 in North Rhine-Westphalia, GermanyIn: BMC Urology Jg. 24 (2024) Nr. 1, 181Online Volltext: dx.doi.org/ (Open Access)
-
Multi-label semantic segmentation of magnetic resonance images of the prostate glandIn: Discover Artificial Intelligence Jg. 4 (2024) Nr. 1, 66Online Volltext: dx.doi.org/ (Open Access)
-
Multiparametric Magnetic Resonance Imaging in Prostate Cancer Screening at the Age of 45 Years : Results from the First Screening Round of the PROBASE TrialIn: European Urology Jg. 85 (2024) Nr. 2, S. 105 - 111Online Volltext: dx.doi.org/ (Open Access)
-
Near-infrared fluorescence lymph node template region dissection plus backup lymphadenectomy in open radical cystectomy for bladder cancer using an innovative handheld device : A single center experienceIn: Journal of Surgical Oncology Jg. 129 (2024) Nr. 7, S. 1325 - 1331Online Volltext: dx.doi.org/ (Open Access)
-
PRO-P : Evaluating the effect of electronic patient-reported outcome measures monitoring compared with standard care in prostate cancer patients undergoing surgery-study protocol for a randomized controlled trialIn: Trials Jg. 25 (2024) Nr. 1, 754Online Volltext: dx.doi.org/ (Open Access)
-
PSMA Radioligand Therapy in Prostate Cancer Where Are We and Where Are We Heading?In: Clinical Nuclear Medicine Jg. 49 (2024) Nr. 1, S. 45 - 55Online Volltext: dx.doi.org/
-
PSMA-PET follow-up to assess response in patients not receiving PSMA therapy : Is there value beyond localization of disease?In: Theranostics Jg. 14 (2024) Nr. 9, S. 3623 - 3633Online Volltext: dx.doi.org/ (Open Access)
-
PSMA-PET research: addressing challenges and prospects : Authors' replyIn: The Lancet Oncology Jg. 25 (2024) Nr. 11, e533Online Volltext: dx.doi.org/
-
Poly (ADP-ribose) Polymerase Inhibitors Have Comparable Efficacy with Platinum Chemotherapy in Patients with BRCA-positive Metastatic Castration-resistant Prostate Cancer : A Systematic Review and Meta-analysisIn: European Urology Oncology Jg. 7 (2024) Nr. 3, S. 365 - 375Online Volltext: dx.doi.org/ (Open Access)
-
Predictors of Early Continence Recovery Following Radical Prostatectomy, Including Transperineal Ultrasound to Evaluate the Membranous Urethra Length (CHECK-MUL Study)In: Diagnostics Jg. 14 (2024) Nr. 8, 853Online Volltext: dx.doi.org/ (Open Access)
-
Prognostic Implications of ⁶⁸Ga-FAPI-46 PET/CT-Derived Parameters on Overall Survival in Various Types of Solid TumorsIn: Journal of Nuclear Medicine (JNM) Jg. 65 (2024) Nr. 7, S. 1027 - 1034Online Volltext: dx.doi.org/
-
Prostate-specific Membrane Antigen Positron Emission Tomography–detected Disease Extent and Overall Survival of Patients with High-risk Nonmetastatic Castration-resistant Prostate Cancer : An International Multicenter Retrospective StudyIn: European Urology Jg. 85 (2024) Nr. 6, S. 511 - 516Online Volltext: dx.doi.org/ (Open Access)
-
RECIP 1.0 Predicts Progression-Free Survival After [¹⁷⁷Lu]Lu-PSMA Radiopharmaceutical Therapy in Patients with Metastatic Castration-Resistant Prostate CancerIn: Journal of Nuclear Medicine (JNM) Jg. 65 (2024) Nr. 6, S. 917 - 922Online Volltext: dx.doi.org/
-
Randomized Trial of Prostate-Specific Membrane Antigen PET/CT Before Definitive Radiotherapy for Unfavorable Intermediate- and High-Risk Prostate Cancer (PSMA-dRT Trial)In: Journal of Nuclear Medicine (JNM) Jg. 65 (2024) Nr. 7, S. 1076 - 1079Online Volltext: dx.doi.org/
-
Re: Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial CancerIn: European Urology Jg. 86 (2024) Nr. 3, S. 280 - 281Online Volltext: dx.doi.org/
-
Recurrent prostate cancer : combined role for MRI and PSMA-PET in ⁶⁸Ga-PSMA-11 PET/MRIIn: European Radiology Jg. 34 (2024) Nr. 7, S. 4789 - 4800Online Volltext: dx.doi.org/ (Open Access)
-
Risk factors for ureteroenteric stricture after radical cystectomy and urinary diversion : A systematic reviewIn: Arab Journal of Urology Jg. 22 (2024) Nr. 1, S. 61 - 69Online Volltext: dx.doi.org/ (Open Access)
-
Risk-adjusted Screening for Prostate Cancer—Defining the Low-risk Group by Data from the PROBASE TrialIn: European Urology (2024) in pressOnline Volltext: dx.doi.org/ (Open Access)
-
Safety and Efficacy of Extended Therapy with [¹⁷⁷Lu]Lu-PSMA : A German Multicenter StudyIn: Journal of Nuclear Medicine (JNM) Jg. 65 (2024) Nr. 6, S. 909 - 916Online Volltext: dx.doi.org/
-
Safety and quality of cystectomy and pelvic lymph node dissection after neoadjuvant durvalumab and cisplatin/gemcitabineIn: BJU International (BJUI) Jg. 134 (2024) Nr. 3, S. 388 - 397Online Volltext: dx.doi.org/
-
Screening for Prostate Cancer with Prostate-specific AntigenIn: European Urology Open Science (2024) in pressOnline Volltext: dx.doi.org/ (Open Access)
-
Surface CD52, CD84, and PTGER2 mark mature PMN-MDSCs from cancer patients and G-CSF-treated donorsIn: Cell Reports Medicine Jg. 5 (2024) Nr. 2, 101380Online Volltext: dx.doi.org/ (Open Access)
-
The DETECT Trial : Are We on the Verge of Precision Surgery in Primary Prostate Cancer?In: Journal of Nuclear Medicine (JNM) Jg. 65 (2024) Nr. 3, S. 430 - 431Online Volltext: dx.doi.org/ (Open Access)
-
The current role of pentafecta in the reporting of radical cystectomy outcomes : a scoping reviewIn: Translational Andrology and Urology Jg. 13 (2024) Nr. 6, S. 1037 - 1048Online Volltext: dx.doi.org/ (Open Access)
-
The impact of double-J ureteral stenting before radical cystectomy on the development of upper tract urothelial carcinomaIn: Minerva Urology and Nephrology Jg. 76 (2024) Nr. 4, S. 442 - 451Online Volltext: dx.doi.org/
-
Transient Decrease in Sperm Motility after PlateletpheresisIn: Exposure and Health Jg. 16 (2024) Nr. 5, S. 1263 - 1277Online Volltext: dx.doi.org/ (Open Access)
-
Value-Based Health Care for Prostate Cancer Centers by Implementing Specific Key Performance Indicators Using a Balanced Score CardIn: Healthcare Jg. 12 (2024) Nr. 10, 991Online Volltext: dx.doi.org/ (Open Access)
-
18F-PSMA Cerenkov Luminescence and Flexible Autoradiography Imaging in a Prostate Cancer Mouse Model and First Results of a Radical Prostatectomy Feasibility Study in MenIn: Journal of Nuclear Medicine (JNM) Jg. 64 (2023) Nr. 4, S. 598 - 604Online Volltext: dx.doi.org/ (Open Access)
-
A Drop-in Gamma Probe for Minimally Invasive Sentinel Lymph Node Dissection in Prostate Cancer : Preclinical Evaluation and Interim Results From a Multicenter Clinical TrialIn: Clinical Nuclear Medicine Jg. 48 (2023) Nr. 3, S. 213 - 220Online Volltext: dx.doi.org/
-
Adherence to a risk-adapted screening strategy for prostate cancer : First results of the PROBASE trialIn: International Journal of Cancer Jg. 152 (2023) Nr. 5, S. 854 - 864Online Volltext: dx.doi.org/ (Open Access)
-
Analysing the tumor transcriptome of prostate cancer to predict efficacy of Lu-PSMA therapyIn: Journal for ImmunoTherapy of Cancer Jg. 11 (2023) Nr. 10, e007354Online Volltext: dx.doi.org/ (Open Access)
-
Clinical characteristics associated with falls in patients with non-metastatic castration-resistant prostate cancer treated with apalutamideIn: Prostate Cancer and Prostatic Diseases Jg. 26 (2023) S. 156 - 161Online Volltext: dx.doi.org/ (Open Access)
-
Clinical sequencing identifies potential actionable alterations in a high rate of urachal and primary bladder adenocarcinomasIn: Cancer Medicine Jg. 12 (2023) Nr. 7, S. 9041 CA Szarvas - 9054Online Volltext: dx.doi.org/ (Open Access)
-
Comparative proteome and serum analysis identified FSCN1 as a marker of abiraterone resistance in castration-resistant prostate cancerIn: Prostate Cancer and Prostatic Diseases Jg. 27 (2023) Nr. 3, S. 451 - 456Online Volltext: dx.doi.org/ (Open Access)
-
Correction to: Clinical characteristics associated with falls in patients with non-metastatic castration-resistant prostate cancer treated with apalutamideIn: Prostate Cancer and Prostatic Diseases Jg. 26 (2023) Nr. 4, 813Online Volltext: dx.doi.org/ (Open Access)
-
Cumulative sum analysis (CUSUM) for evaluating learning curve (LC) of robotic-assisted laparoscopic partial nephrectomy (RALPN)In: Journal of Robotic Surgery Jg. 17 (2023) Nr. 5, S. 2089 - 2098Online Volltext: dx.doi.org/
-
DGN-Handlungsempfehlung (S1-Leitlinie) : PSMA-Liganden-PET/CT in der Diagnostik des Prostatakarzinoms - Stand: 01/2022 - AWMF-Registernummer: 031-055In: Nuklearmedizin = Nuclear Medicine Jg. 62 (2023) Nr. 1, S. 5 - 19Online Volltext: dx.doi.org/
-
Das Primärstaging mittels PSMA-PET verbessert die Vorhersage von ProstatakarzinomrezidivenIn: Die Urologie Jg. 62 (2023) Nr. 12, S. 1326 - 1327Online Volltext: dx.doi.org/
-
Detection of Clinically Significant Prostate Cancer Using Targeted Biopsy with Four Cores Versus Target Saturation Biopsy with Nine Cores in Transperineal Prostate Fusion Biopsy : A Prospective Randomized TrialIn: European Urology Oncology Jg. 6 (2023) Nr. 1, S. 49 - 55Online Volltext: dx.doi.org/
-
Diagnosis of female urethral diverticulum using pelvic floor ultrasound and comparison with voiding cystourethrogram (imaging study)In: International Urogynecology Journal Jg. 34 (2023) Nr. 2, S. 563 - 569Online Volltext: dx.doi.org/
-
Digital Rectal Examination Is Not a Useful Screening Test for Prostate CancerIn: European Urology Oncology Jg. 6 (2023) Nr. 6, S. 566 - 573Online Volltext: dx.doi.org/
-
Efficacy of immune checkpoint inhibitor therapy for advanced urothelial carcinoma in real-life clinical practice : results of a multicentric, retrospective studyIn: Scientific Reports Jg. 13 (2023) Nr. 1, 17378Online Volltext: dx.doi.org/ (Open Access)
-
Enfortumab Vedotin in Metastatic Urothelial Carcinoma : Survival and Safety in a European Multicenter Real-world Patient CohortIn: European Urology Open Science Jg. 53 (2023) S. 31 - 37Online Volltext: dx.doi.org/ (Open Access)
-
Fibroblast-Activation Protein PET and Histopathology in a Single-Center Database of 324 Patients and 21 Tumor EntitiesIn: Journal of Nuclear Medicine (JNM) Jg. 64 (2023) Nr. 5, S. 711 - 716Online Volltext: dx.doi.org/ (Open Access)
-
Fractionation versus Adaptation for Compensation of Target Volume Changes during Online Adaptive Radiotherapy for Bladder Cancer : Answers from a Prospective RegistryIn: Cancers Jg. 15 (2023) Nr. 20, 4933Online Volltext: dx.doi.org/ (Open Access)
-
Immune-Checkpoint-Inhibitor Therapy : Principles and Relevance of Biomarkers for Pathologists and OncologistsIn: Advances in Anatomic Pathology Jg. 30 (2023) Nr. 3, S. 160 - 166Online Volltext: dx.doi.org/
-
Intraoperative Molecular Positron Emission Tomography Imaging for Intraoperative Assessment of Radical Prostatectomy SpecimensIn: European Urology Open Science Jg. 54 (2023) S. 28 - 32Online Volltext: dx.doi.org/ (Open Access)
-
Is an Endorectal Balloon Beneficial for Rectal Sparing after Spacer Implantation in Prostate Cancer Patients Treated with Hypofractionated Intensity-Modulated Proton Beam Therapy? : A Dosimetric and Radiobiological Comparison StudyIn: Current Oncology Jg. 30 (2023) Nr. 1, S. 758 - 768Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Is ¹⁸F-FDG PET Needed to Assess ¹⁷⁷Lu-PSMA Therapy Eligibility? : A VISION-like, Single-Center AnalysisIn: Journal of Nuclear Medicine (JNM) Jg. 64 (2023) Nr. 5, S. 731 - 737Online Volltext: dx.doi.org/ (Open Access)
-
MR-Guided Transurethral Ultrasound Ablation of Prostate Cancer : Initial Experience of Monitoring Tumor Response by Dynamic Apparent Diffusion Coefficient Measurements at 3.0 TIn: Urologia Internationalis Jg. 107 (2023) Nr. 7, S. 684 - 692Online Volltext: dx.doi.org/
-
Metastatic Prostate Cancer : A Review of Current Treatment Options and Promising New ApproachesIn: Cancers Jg. 15 (2023) Nr. 2, 461Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Neue Therapieansätze und Studienübersicht beim metastasierten hormonsensitiven ProstatakarzinomIn: Die Urologie Jg. 62 (2023) Nr. 4, S. 369 - 375Online Volltext: dx.doi.org/
-
Next generation radiotheranostics promoting precision medicineIn: Annals of Oncology Jg. 34 (2023) Nr. 6, S. 507 - 519Online Volltext: dx.doi.org/
-
Perioperative Chemoimmunotherapy With Durvalumab for Muscle-Invasive Urothelial Carcinoma : Primary Analysis of the Single-Arm Phase II Trial SAKK 06/17In: Journal of Clinical Oncology (JCO) Jg. 41 (2023) Nr. 33, S. 5131 - 5139Online Volltext: dx.doi.org/ (Open Access)
-
Photodynamische transurethrale Resektion der Blase (TURB): mehr Schein als Sein : Ein Kommentar zur randomisierten StudieIn: Die Urologie Jg. 62 (2023) Nr. 2, S. 181 - 183Online Volltext: dx.doi.org/
-
Pre-treatment soluble PD-L1 as a predictor of overall survival for immune checkpoint inhibitor therapy : a systematic review and meta-analysisIn: Cancer Immunology, Immunotherapy Jg. 72 (2023) Nr. 5, S. 1061 - 1073Online Volltext: dx.doi.org/ (Open Access)
-
Predictive value of molecular subtypes and APOBEC3G for adjuvant chemotherapy in urothelial bladder cancerIn: Cancer Medicine Jg. 12 (2023) Nr. 5, S. 5222 - 5232Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Primary Whole-gland Ablation for the Treatment of Clinically Localized Prostate Cancer : A Focal Therapy Society Best Practice StatementIn: European Urology Jg. 84 (2023) Nr. 6, S. 547 - 560Online Volltext: dx.doi.org/
-
Profile of the multicenter cohort of the German Cancer Consortium’s Clinical Communication PlatformIn: European Journal of Epidemiology Jg. 38 (2023) Nr. 5, S. 573 - 586Online Volltext: dx.doi.org/ (Open Access)
-
Re: First-in-Human Study of the Radioligand ⁶⁸Ga-N188 Targeting Nectin-4 for PET/CT Imaging of Advanced Urothelial Carcinoma : Navigating Metastatic Urothelial Cancer with Nectin-4 PET/CTIn: European Urology Jg. 84 (2023) Nr. 5, S. 514 - 515Online Volltext: dx.doi.org/
-
Response Evaluation Criteria in PSMA PET/CT (RECIP 1.0) in Metastatic Castration-resistant Prostate CancerIn: Radiology Jg. 308 (2023) Nr. 1, e222148Online Volltext: dx.doi.org/
-
Risk and predictors of adverse pathology after radical prostatectomy in patients diagnosed with IUSP 1–2 prostate cancer at MRI-targeted biopsy : a multicenter analysisIn: World Journal of Urology Jg. 41 (2023) Nr. 2, S. 427 - 434Online Volltext: dx.doi.org/ (Open Access)
-
Second Version of the Prostate Cancer Molecular Imaging Standardized Evaluation Framework Including Response Evaluation for Clinical Trials (PROMISE V2)In: European Urology Jg. 83 (2023) Nr. 5, S. 405 - 412Online Volltext: dx.doi.org/ (Open Access)
-
Small Suspicious Lymph Nodes Detected on Ultrahigh-field Magnetic Resonance Imaging (MRI) in Patients with Prostate Cancer with High Risk of Nodal Metastases : The First In-patient Study on Ultrasmall Superparamagnetic Iron Oxide-enhanced 7T MRIIn: European Urology Jg. 83 (2023) Nr. 4, S. 375 - 377Online Volltext: dx.doi.org/ (Open Access)
-
Standardized PSMA-PET Imaging of Advanced Prostate CancerIn: Seminars in Nuclear Medicine Jg. 54 (2023) Nr. 1, S. 60 - 68Online Volltext: dx.doi.org/
-
Systematische oder gezielte Fusionsbiopsie der ProstataIn: Die Urologie Jg. 62 (2023) Nr. 5, S. 464 - 472Online Volltext: dx.doi.org/
-
Therapeutic sensitivity to standard treatments in BRCA positive metastatic castration-resistant prostate cancer patients : A systematic review and meta-analysisIn: Prostate Cancer and Prostatic Diseases Jg. 26 (2023) Nr. 4, S. 665 - 672Online Volltext: dx.doi.org/ (Open Access)
-
Unspecific ¹⁸F-PSMA-1007 Bone Uptake Evaluated Through PSMA-11 PET, Bone Scanning, and MRI Triple Validation in Patients with Biochemical Recurrence of Prostate CancerIn: Journal of Nuclear Medicine (JNM) Jg. 64 (2023) Nr. 5, S. 738 - 743Online Volltext: dx.doi.org/ (Open Access)
-
A quantitative polymerase chain reaction based method for molecular subtype classification of urinary bladder cancer : Stromal gene expressions show higher prognostic values than intrinsic tumor genesIn: International Journal of Cancer Jg. 150 (2022) Nr. 5, S. 856 - 867Online Volltext: dx.doi.org/ (Open Access)
-
A randomized trial of risk-adapted screening for prostate cancer in young men : Results of the first screening round of the PROBASE trialIn: International Journal of Cancer Jg. 150 (2022) Nr. 11, S. 1861 - 1869Online Volltext: dx.doi.org/ (Open Access)
-
Apalutamide Compared with Darolutamide for the Treatment of Non-metastatic Castration-Resistant Prostate Cancer : Efficacy and Tolerability in a Matching-Adjusted Indirect ComparisonIn: Advances in Therapy Jg. 39 (2022) Nr. 1, S. 518 - 531Online Volltext: dx.doi.org/ (Open Access)
-
Apalutamide compared with darolutamide for the treatment of non-metastatic castration resistant prostate cancer : efficacy and tolerability in a matching-adjusted indirect comparisonIn: Onkourologija (= Cancer Urology) Jg. 18 (2022) Nr. 1, S. 77 - 89Online Volltext: dx.doi.org/ (Open Access)
-
Clinical Importance of a Peritoneal Interposition Flap to Prevent Symptomatic Lymphoceles after Robot-Assisted Radical Prostatectomy and Pelvic Lymph Node Dissection : A Systematic Review and Meta-AnalysisIn: Urologia Internationalis Jg. 106 (2022) Nr. 1, S. 28 - 34Online Volltext: dx.doi.org/ (Open Access)
-
Clinical outcome and quality of life in octogenarian patients with muscle-invasive urothelial carcinoma of the bladder treated with radical cystectomy or transurethral resection of the bladder tumor : a retrospective analysis of 143 patientsIn: International Urology and Nephrology Jg. 54 (2022) Nr. 1, S. 71 - 79Online Volltext: dx.doi.org/ (Open Access)
-
Comparative analysis of Bricker versus Wallace ureteroenteric anastomosis and identification of predictors for postoperative ureteroenteric strictureIn: Langenbeck's Archives of Surgery Jg. 407 (2022) Nr. 3, S. 1233 - 1240Online Volltext: dx.doi.org/ (Open Access)
-
Comparative proteome analysis identified CD44 as a possible serum marker for docetaxel resistance in castration-resistant prostate cancerIn: Journal of Cellular and Molecular Medicine Jg. 26 (2022) Nr. 4, S. 1332 - 1337Online Volltext: dx.doi.org/ (Open Access)
-
Correlation between symptoms and imaging findings including pelvic floor ultrasound to improve the symptom-based diagnosis of female urethral diverticulum (CHECK-UD study)In: International Urogynecology Journal Jg. 33 (2022) Nr. 8, S. 2267 - 2274Online Volltext: dx.doi.org/
-
Deep Prostate-specific Antigen Response following Addition of Apalutamide to Ongoing Androgen Deprivation Therapy and Long-term Clinical Benefit in SPARTANIn: European Urology Jg. 81 (2022) Nr. 2, S. 184 - 192Online Volltext: dx.doi.org/ (Open Access)
-
Dosimetric feasibility of moderately hypofractionated/dose escalated radiation therapy for localised prostate cancer with intensity-modulated proton beam therapy using simultaneous integrated boost (SIB-IMPT) and impact of hydrogel prostate-rectum spacerIn: Radiation Oncology Jg. 17 (2022) Nr. 1, 64Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
EAU-EANM Consensus Statements on the Role of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Patients with Prostate Cancer and with Respect to [¹⁷⁷Lu]Lu-PSMA Radioligand TherapyIn: European Urology Oncology Jg. 5 (2022) Nr. 5, S. 530 - 536Online Volltext: dx.doi.org/ (Open Access)
-
Elevated Pre-Treatment Serum MMP-7 Levels Are Associated with the Presence of Metastasis and Poor Survival in Upper Tract Urothelial CarcinomaIn: Biomedicines Jg. 10 (2022) Nr. 3, 698Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Health-related Quality of Life at the SPARTAN Final Analysis of Apalutamide for Nonmetastatic Castration-resistant Prostate Cancer Patients Receiving Androgen Deprivation TherapyIn: European Urology Focus Jg. 8 (2022) Nr. 4, S. 958 - 967Online Volltext: dx.doi.org/ (Open Access)
-
High Pretreatment Serum PD-L1 Levels Are Associated with Muscle Invasion and Shorter Survival in Upper Tract Urothelial CarcinomaIn: Biomedicines Jg. 10 (2022) Nr. 10, 2560Online Volltext: dx.doi.org/ (Open Access)
-
Impact of COVID-19 crisis on medical care of patients with metastasized uro-oncologic disease under systemic cancer therapy : a multicenter study in German university hospitalsIn: World Journal of Urology Jg. 40 (2022) Nr. 2, S. 409 - 418Online Volltext: dx.doi.org/ (Open Access)
-
Impact of Surgical Experience Before Robot-assisted Partial Nephrectomy on Surgical Outcomes : A Multicenter Analysis of 2500 PatientsIn: European Urology Open Science Jg. 46 (2022) S. 45 - 52Online Volltext: dx.doi.org/ (Open Access)
-
Kombinierte Hormontherapie beim lokal begrenzten ProstatakarzinomIn: Die Urologie Jg. 61 (2022) Nr. 9, S. 660 - 662Online Volltext: dx.doi.org/
-
Lessons learned after one year of COVID-19 from a urologist and radiotherapist view : A German survey on prostate cancer diagnosis and treatmentIn: PLoS ONE Jg. 17 (2022) Nr. 6, e0269827Online Volltext: dx.doi.org/ (Open Access)
-
Novel Framework for Treatment Response Evaluation Using PSMA PET/CT in Patients with Metastatic Castration-Resistant Prostate Cancer (RECIP 1.0) : An International Multicenter StudyIn: Journal of Nuclear Medicine (JNM) Jg. 63 (2022) Nr. 11, S. 1651 - 1658Online Volltext: dx.doi.org/ (Open Access)
-
Onkologische Theranostik in der NuklearmedizinIn: Die Onkologie Jg. 28 (2022) Nr. 7, S. 612 - 622Online Volltext: dx.doi.org/
-
Onkologische Theranostik in der NuklearmedizinIn: Die Radiologie Jg. 62 (2022) Nr. 10, S. 875 - 884Online Volltext: dx.doi.org/
-
Proteasomal Processing Immune Escape Mechanisms in Platinum-Treated Advanced Bladder CancerIn: Genes Jg. 13 (2022) Nr. 3, 422Online Volltext: dx.doi.org/ (Open Access)
-
Proteome profiling of enzalutamide-resistant cell lines and serum analysis identified ALCAM as marker of resistance in castration-resistant prostate cancerIn: International Journal of Cancer Jg. 151 (2022) Nr. 8, S. 1405 - 1419Online Volltext: dx.doi.org/ (Open Access)
-
Radiation Protection and Occupational Exposure on ⁶⁸Ga-PSMA-11-Based Cerenkov Luminescence Imaging Procedures in Robot-Assisted ProstatectomyIn: Journal of Nuclear Medicine (JNM) Jg. 63 (2022) Nr. 9, S. 1349 - 1356Online Volltext: dx.doi.org/ (Open Access)
-
Re: Abiraterone Acetate and Prednisolone With or Without Enzalutamide for High-risk Non-metastatic Prostate Cancer : A Meta-analysis of Primary Results from Two Randomized Controlled Phase 3 Trials of the STAMPEDE Platform ProtocolIn: European Urology Jg. 81 (2022) Nr. 6, S. 621Online Volltext: dx.doi.org/
-
Re: Active Surveillance Plus Enzalutamide Monotherapy vs Active Surveillance Alone in Patients with Low-risk or Intermediate-risk Localized Prostate Cancer : The ENACT Randomized Clinical TrialIn: European Urology Jg. 82 (2022) Nr. 5, S. 572Online Volltext: dx.doi.org/
-
Repeatability of ⁶⁸Ga-PSMA-HBED-CC PET/CT-Derived Total Molecular Tumor VolumeIn: Journal of Nuclear Medicine (JNM) Jg. 63 (2022) Nr. 5, S. 746 - 753Online Volltext: dx.doi.org/ (Open Access)
-
Reply to Nikolaos Grivas, Nikolaos Kalampokis, Markos Karavitakis, Ioannis Leotsakos, Ioannis Katafigiotis, and Henk van der Poel’s Letter to the Editor re: Bara Barakat, Hazem Othman, Ulrich Gauger, Ingmar Wolff, Boris Hadaschik, Christian Rehme. Retzius Sparing Radical Prostatectomy Versus Robot-assisted Radical Prostatectomy: Which Technique Is More Beneficial for Prostate Cancer Patients (MASTER Study)? A Systematic Review and Meta-analysis. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2021.08.003In: European Urology Focus Jg. 8 (2022) Nr. 5, S. 1556Online Volltext: dx.doi.org/
-
Retrograde Pyelography in the Presence of Urothelial Bladder Cancer Does Not Affect the Risk of Upper Tract Urothelial Cancer : A Retrospective Analysis of a Single-Centre CohortIn: Urologia Internationalis Jg. 106 (2022) S. 638 - 643Online Volltext: dx.doi.org/ (Open Access)
-
Retzius Sparing Radical Prostatectomy Versus Robot-assisted Radical Prostatectomy : Which Technique Is More Beneficial for Prostate Cancer Patients (MASTER Study)? A Systematic Review and Meta-analysisIn: European Urology Focus Jg. 8 (2022) Nr. 4, S. 1060 - 1071Online Volltext: dx.doi.org/
-
Strukturierte Befundung am Beispiel des Prostatakarzinoms : Selbstentwicklung einer digitalen Lösung für ProstatastanzbiopsienIn: Die Pathologie Jg. 43 (2022) Nr. Suppl. 1, S. 94 - 100Online Volltext: dx.doi.org/
-
The Prognostic Value of Cytokeratin and Extracellular Collagen Expression in Urinary Bladder CancerIn: Current Molecular Medicine Jg. 22 (2022) Nr. 10, S. 941 - 949Online Volltext: dx.doi.org/
-
Three-dimensional Magnetic Resonance Imaging-based Printed Models of Prostate Anatomy and Targeted Biopsy-proven Index Tumor to Facilitate Patient-tailored Radical Prostatectomy : A Feasibility StudyIn: European Urology Oncology Jg. 5 (2022) Nr. 3, S. 357 - 361Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Virtual Biopsy : Just an AI Software or a Medical Procedure?In: Journal of Nuclear Medicine (JNM) Jg. 63 (2022) Nr. 4, S. 511 - 513Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Apalutamide and Overall Survival in Prostate CancerIn: European Urology Jg. 79 (2021) Nr. 1, S. 150 - 158Online Volltext: dx.doi.org/ (Open Access)
-
Association of molecular subtypes with differential outcome to apalutamide treatment in nonmetastatic castration-resistant prostate cancerIn: JAMA Oncology Jg. 7 (2021) Nr. 7, S. 1005 - 1014Online Volltext: dx.doi.org/ (Open Access)
-
Beta radioguided surgery: towards routine implementation?In: The Quarterly Journal of Nuclear Medicine and Molecular Imaging Jg. 65 (2021) Nr. 3, S. 229 - 243Online Volltext: dx.doi.org/
-
Botulinum Toxin A in Pediatric Day-Time Lower Urinary Tract Conditions : A Single Center ExperienceIn: Journal of Urology and Renal Diseases Jg. 6 (2021) Nr. 6, 1236Online Volltext: dx.doi.org/ (Open Access)
-
Comprehensive analysis of serum chromogranin A and neuron-specific enolase levels in localized and castration-resistant prostate cancerIn: BJU International (BJUI) Jg. 127 (2021) Nr. 1, S. 44 - 55Online Volltext: dx.doi.org/
-
Consensus statements on PSMA PET/CT response assessment criteria in prostate cancerIn: European Journal of Nuclear Medicine and Molecular Imaging Jg. 48 (2021) Nr. 2, S. 469 - 476Online Volltext: dx.doi.org/ (Open Access)
-
Correction to : COVID-19 research ; promising tracks leading to uro-oncologyIn: International Urology and Nephrology Jg. 53 (2021) Nr. 1, S. 95Online Volltext: dx.doi.org/ (Open Access)
-
Detection of Significant Prostate Cancer Using Target Saturation in Transperineal Magnetic Resonance Imaging/Transrectal Ultrasonography–fusion BiopsyIn: European Urology Focus Jg. 7 (2021) Nr. 6, S. 1300 - 1307Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Determinants of self-reported functional status (EPIC-26) in prostate cancer patients prior to treatmentIn: World Journal of Urology Jg. 39 (2021) Nr. 1, S. 27 - 36Online Volltext: dx.doi.org/ (Open Access)
-
Die Therapie des primär oligometastasierten ProstatakarzinomsIn: Der Urologe Jg. 60 (2021) Nr. 12, S. 1527 - 1533Online Volltext: dx.doi.org/
-
Drug and molecular radiotherapy combinations for metastatic castration resistant prostate cancerIn: Nuclear Medicine and Biology Jg. 96-97 (2021) S. 101 - 111Online Volltext: dx.doi.org/ (Open Access)
-
Elektive Strahlentherapie pelviner Lymphknoten beim High-risk-Prostatakarzinom? : Bewertung der Relation zwischen der relativen Risikoreduktion eines PSA-Rezidivs (prostataspezifisches Antigen) innerhalb von 5 Jahren und einem absoluten ÜberlebensvorteilIn: Der Urologe Jg. 60 (2021) Nr. 8, S. 1051 - 1053Online Volltext: dx.doi.org/
-
Enzalutamide enhances psma expression of psma-low prostate cancerIn: International Journal of Molecular Sciences (IJMS) Jg. 22 (2021) Nr. 14, 7431Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
High fibroblast-activation-protein expression in castration-resistant prostate cancer supports the use of FAPI-molecular theranosticsIn: European Journal of Nuclear Medicine and Molecular Imaging Jg. 49 (2021) S. 385 - 389Online Volltext: dx.doi.org/ (Open Access)
-
High serum pd-l1 levels are associated with poor survival in urothelial cancer patients treated with chemotherapy and immune checkpoint inhibitor therapyIn: Cancers Jg. 13 (2021) Nr. 11, 2548Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
High-intensity focused ultrasound (HIFU) hemiablation of the prostate: Late follow-up MRI findings in non-recurrent patientsIn: European Journal of Radiology Jg. 144 (2021) 109957Online Volltext: dx.doi.org/
-
Identification of PCWG3 Target Populations Is More Accurate and Reproducible with PSMA PET Than with Conventional Imaging : A Multicenter Retrospective StudyIn: Journal of Nuclear Medicine (JNM) Jg. 62 (2021) Nr. 5, S. 675 - 678Online Volltext: dx.doi.org/ (Open Access)
-
Implementation of radioguided surgery in prostate cancerIn: The Quarterly Journal of Nuclear Medicine and Molecular Imaging Jg. 65 (2021) Nr. 3, S. 202 - 214Online Volltext: dx.doi.org/
-
Kann die Progression eines Prostatakarzinoms während Active Surveillance durch serielle Magnetresonanztomographie verlässlich diagnostiziert werden?In: Der Urologe Jg. 60 (2021) Nr. 12, S. 1594 - 1597Online Volltext: dx.doi.org/
-
Lokale Strahlentherapie der Prostata mit Samenblasenbasis allein oder mit elektiver Bestrahlung pelviner Lymphknotenstationen beim Hochrisiko-Prostatakarzinom? : Ergebnisse der randomisierten POP-RT-StudieIn: Strahlentherapie und Onkologie: Journal of Radiation Oncology, Biology, Physics Jg. 197 (2021) Nr. 10, S. 939 - 942Online Volltext: dx.doi.org/ (Open Access)
-
Lokale und Metastasen-gerichtete Therapieoptionen beim oligometastasierten ProstatakarzinomIn: Aktuelle Urologie Jg. 52 (2021) Nr. 2, S. 149 - 154Online Volltext: dx.doi.org/
-
M0CRPC overview of management optionsIn: World Journal of Urology Jg. 39 (2021) Nr. 2, S. 349 - 356Online Volltext: dx.doi.org/
-
MMP-7 Serum and Tissue Levels Are Associated with Poor Survival in Platinum-Treated Bladder Cancer PatientsIn: Diagnostics Jg. 11 (2021) Nr. 1, 48Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Mechanisms and markers of resistance to androgen signaling inhibitors in patients with metastatic castration-resistant prostate cancerIn: Urologic Oncology: Seminars and Original Investigations Jg. 39 (2021) Nr. 10, S. 728.e13 - 728.e24Online Volltext: dx.doi.org/ (Open Access)
-
Nomograms to predict outcomes after ¹⁷⁷Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer : An international, multicentre, retrospective studyIn: The Lancet Oncology Jg. 22 (2021) Nr. 8, S. 1115 - 1125Online Volltext: dx.doi.org/ (Open Access)
-
Nuclear medicine theranostics comes of ageIn: The Lancet Oncology Jg. 22 (2021) Nr. 11, S. 1497 - 1498Online Volltext: dx.doi.org/
-
PSMA PET total tumor volume predicts outcome of patients with advanced prostate cancer receiving [¹⁷⁷Lu]Lu-PSMA-617 radioligand therapy in a bicentric analysisIn: European Journal of Nuclear Medicine and Molecular Imaging Jg. 48 (2021) Nr. 4, S. 1200 - 1210Online Volltext: dx.doi.org/ (Open Access)
-
PSMA-PET for the assessment of metastatic hormone-sensitive prostate cancer volume of diseaseIn: Journal of Nuclear Medicine (JNM) Jg. 62 (2021) Nr. 12, S. 1747 - 1750Online Volltext: dx.doi.org/ (Open Access)
-
PSMA-ligand PET for early castration-resistant prostate cancer : a retrospective single-center studyIn: Journal of Nuclear Medicine (JNM) Jg. 62 (2021) Nr. 1, S. 88 - 91Online Volltext: dx.doi.org/ (Open Access)
-
Phase 3 multicenter randomized trial of PSMA PET/CT prior to definitive radiation therapy for unfavorable intermediate-risk or high-risk prostate cancer [PSMA dRT] : study protocolIn: BMC Cancer Jg. 21 (2021) 512Online Volltext: dx.doi.org/ (Open Access)
-
Positron Emission Tomography and Whole-body Magnetic Resonance Imaging for Metastasis-directed Therapy in Hormone-sensitive Oligometastatic Prostate Cancer After Primary Radical Treatment : A Systematic ReviewIn: European Urology Oncology Jg. 4 (2021) Nr. 5, S. 714 - 730Online Volltext: dx.doi.org/
-
Prostate specific membrane antigen-radio guided surgery using Cerenkov luminescence imaging : Utilization of a short-pass filter to reduce technical pitfallsIn: Translational Andrology and Urology Jg. 10 (2021) Nr. 10, S. 3972 - 3985Online Volltext: dx.doi.org/ (Open Access)
-
Prostate-specific Membrane Antigen Imaging and Theranostics Impact Patient OutcomesIn: European Urology Focus Jg. 7 (2021) Nr. 2, S. 229 - 230Online Volltext: dx.doi.org/
-
Prostate-specific Membrane Antigen–based Imaging of Castration-resistant Prostate CancerIn: European Urology Focus Jg. 7 (2021) Nr. 2, S. 279 - 287Online Volltext: dx.doi.org/
-
Re: Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate CancerIn: European Urology Jg. 80 (2021) Nr. 4, S. 520 - 521Online Volltext: dx.doi.org/
-
Re: Nivolumab plus Cabozantinib Versus Sunitinib for Advanced Renal-cell CarcinomaIn: European Urology Jg. 80 (2021) Nr. 2, S. 256 - 257Online Volltext: dx.doi.org/
-
Re: The Key Combined Value of Multiparametric Magnetic Resonance Imaging, and Magnetic Resonance Imaging–targeted and Concomitant Systematic Biopsies for the Prediction of Adverse Pathological Features in Prostate Cancer Patients Undergoing Radical ProstatectomyIn: European Urology Jg. 79 (2021) Nr. 1, S. 164 - 165Online Volltext: dx.doi.org/
-
Retroperitoneal Versus Transperitoneal Robotic Partial Nephrectomy : A Multicenter Matched-pair AnalysisIn: European Urology Focus Jg. 7 (2021) Nr. 6, S. 1363 - 1370Online Volltext: dx.doi.org/
-
Stone extraction with loop ureteral catheter versus ureteroscopy in small distal ureteral stones—retrospective comparison of 547 consecutive patientsIn: Translational Andrology and Urology Jg. 10 (2021) Nr. 1, S. 87 - 95Online Volltext: dx.doi.org/ (Open Access)
-
Superior early and long-term continence following early micturition on day 2 after robot-assisted radical prostatectomy : A randomized prospective trialIn: World Journal of Urology Jg. 39 (2021) Nr. 3, S. 771 - 777Online Volltext: dx.doi.org/
-
The Biomarker Potential of Caveolin-1 in Penile CancerIn: Frontiers in Oncology Jg. 11 (2021) S. 606122Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
The prognostic value of serum MMP-7 levels in prostate cancer patients who received docetaxel, abiraterone, or enzalutamide therapyIn: Urologic Oncology: Seminars and Original Investigations Jg. 39 (2021) Nr. 5, S. 296.e11 - 296.e19Online Volltext: dx.doi.org/ (Open Access)
-
The value of an additional scrotal suture during orchidopexyIn: Journal of Pediatric Urology Jg. 17 (2021) Nr. 1, S. 82.e1 - 82.e5Online Volltext: dx.doi.org/
-
Therapie des nicht-fernmetastasierten CRPC : Androgenrezeptorinhibition als neuer Therapiestandard beim nicht-fernmetastasierten kastrationsresistenten Prostatakarzinom mit hohem MetastasierungsrisikoIn: Der Urologe Jg. 60 (2021) Nr. 6, S. 753 - 759Online Volltext: dx.doi.org/ (Open Access)
-
Transrectal Ultrasound Guided Hydrodistension : A New Surgical Way in Transgender SurgeryIn: The Journal of Sexual Medicine Jg. 18 (2021) Nr. 6, S. 1134 - 1140Online Volltext: dx.doi.org/
-
Zystisches Nephrom bei einem 15 Monate alten Patienten mit DICER1-MutationIn: Der Urologe Jg. 60 (2021) Nr. 6, S. 776 - 779Online Volltext: dx.doi.org/
-
Diagnosis and Empirical Treatment of Urinary Tract Infections in Urologic OutpatientsIn: Urologia Internationalis Jg. 104 (2020) Nr. 7-8, S. 617 - 624Online Volltext: dx.doi.org/
-
Editorial Comment : [zu Optimal Timing of Prostate Specific Membrane Antigen Positron Emission Tomography/Computerized Tomography for Biochemical Recurrence after Radical Prostatectomy]In: The Journal of Urology Jg. 204 (2020) Nr. 3, S. 510Online Volltext: dx.doi.org/
-
External validation of novel magnetic resonance imaging-based models for prostate cancer predictionIn: BJU International (BJUI) Jg. 125 (2020) Nr. 3, S. 407 - 416Online Volltext: dx.doi.org/
-
First-in-man intraoperative Cerenkov luminescence imaging for oligometastatic prostate cancer using ⁶⁸Ga-PSMA-11In: European Journal of Nuclear Medicine and Molecular Imaging Jg. 47 (2020) Nr. 13, S. 3194 - 3195Online Volltext: dx.doi.org/
-
Intraoperative 68Gallium-PSMA Cerenkov Luminescence Imaging for surgical margins in radical prostatectomy : A feasibility studyIn: Journal of Nuclear Medicine (JNM) Jg. 61 (2020) Nr. 10, S. 1500 - 1506Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Mapping Prostate Cancer Lesions Before and After Unsuccessful Salvage Lymph Node Dissection Using Repeat PSMA PETIn: Journal of Nuclear Medicine (JNM) Jg. 61 (2020) Nr. 7, S. 1037 - 1042Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Matching-Adjusted Indirect Comparison of Health-Related Quality of Life and Adverse Events of Apalutamide Versus Enzalutamide in Non-Metastatic Castration-Resistant Prostate CancerIn: Advances in Therapy Jg. 37 (2020) Nr. 1, S. 512 - 526Online Volltext: dx.doi.org/ (Open Access)
-
Matching-Adjusted Indirect Comparison of the Efficacy of Apalutamide and Enzalutamide with ADT in the Treatment of Non-Metastatic Castration-Resistant Prostate CancerIn: Advances in Therapy Jg. 37 (2020) S. 501 - 511Online Volltext: dx.doi.org/ (Open Access)
-
Narrow-band imaging assisted cystoscopy in the follow-up of patients with transitional cell carcinoma of the bladder : a randomized study in comparison with white light cystoscopyIn: World Journal of Urology Jg. 38 (2020) Nr. 6, S. 1509 - 1515Online Volltext: dx.doi.org/
-
Nuclear Localization of Robo is Associated with Better Survival in Bladder CancerIn: Pathology & Oncology Research Jg. 26 (2020) Nr. 1, S. 253 - 261Online Volltext: dx.doi.org/
-
Prevalence of APC and PTEN Alterations in Urachal CancerIn: Pathology & Oncology Research Jg. 26 (2020) Nr. 4, S. 2773 - 2781Online Volltext: dx.doi.org/ (Open Access)
-
Prostate-specific membrane antigen targeted PET imaging for prostate cancer recurrenceIn: Current Opinion in Urology Jg. 30 (2020) Nr. 5, S. 635 - 640Online Volltext: dx.doi.org/
-
Re: MRI-Targeted, Systematic, and Combined Biopsy for Prostate Cancer DiagnosisIn: European Urology Jg. 78 (2020) Nr. 2, S. 291 - 292Online Volltext: dx.doi.org/
-
Re: Prostate-specific Membrane Antigen PET-CT in Patients with High-risk Prostate Cancer Before Curative-intent Surgery or Radiotherapy (proPSMA) : A Prospective, Randomised, Multi-centre StudyIn: European Urology Jg. 78 (2020) Nr. 3, S. 470 - 471Online Volltext: dx.doi.org/
-
Renal duplication with ureter duplex not following Meyer-Weigert-Rule with development of a megaureter of the lower ureteral segment due to distal stenosis – A case reportIn: Urology Case Reports Jg. 28 (2020) 101038Online Volltext: dx.doi.org/ (Open Access)
-
STIP1 Tissue Expression Is Associated with Survival in Chemotherapy-Treated Bladder Cancer PatientsIn: Pathology & Oncology Research Jg. 26 (2020) Nr. 2, S. 1243 - 1249Online Volltext: dx.doi.org/
-
Serum and tissue syndecan-1 levels in renal cell carcinomaIn: Translational Andrology and Urology Jg. 9 (2020) Nr. 3, S. 1167 - 1176Online Volltext: dx.doi.org/ (Open Access)
-
Soluble syndecan-1 levels are associated with survival in platinum-treated bladder cancer patientsIn: Diagnostics Jg. 10 (2020) Nr. 11, 864Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Therapiekonzepte beim primär oligometastasierten ProstatakarzinomIn: Der Urologe Jg. 59 (2020) Nr. 6, S. 659 - 664Online Volltext: dx.doi.org/
-
To defer or not to defer? : A German longitudinal multicentric assessment of clinical practice in urology during the COVID-19 pandemicIn: PLoS ONE Jg. 15 (2020) Nr. 9, S. e0239027Online Volltext: dx.doi.org/ (Open Access)
-
Urachal cancer in Germany and the USA : An RKI/SEER population-based comparison studyIn: Urologia Internationalis Jg. 104 (2020) Nr. 9-10, S. 803 - 809Online Volltext: dx.doi.org/
-
Was erwartet der Nichtradiologe vom Radiologen?In: Der Radiologe Jg. 60 (2020) Nr. 5, S. 421 - 429Online Volltext: dx.doi.org/
-
Whole-Body Integrated [⁶⁸Ga]PSMA-11-PET/MR Imaging in Patients with Recurrent Prostate Cancer : Comparison with Whole-Body PET/CT as the Standard of ReferenceIn: Molecular Imaging and Biology Jg. 22 (2020) Nr. 3, S. 788 - 796Online Volltext: dx.doi.org/
-
“TREXIT 2020” : Why the time to abandon transrectal prostate biopsy starts nowIn: Prostate Cancer and Prostatic Diseases Jg. 23 (2020) Nr. 1, S. 62 - 65Online Volltext: dx.doi.org/ (Open Access)
-
A Systematic Review on the Role of Imaging in Early Recurrent Prostate CancerIn: European Urology Oncology Jg. 2 (2019) Nr. 1, S. 47 - 76Online Volltext: dx.doi.org/ (Open Access)
-
Active Surveillance und die moderne Diagnostik des Prostatatkarzinoms : Multiparametrische MRT, Fusionsbiopsien und neue genetische BiomarkerIn: Der Onkologe Jg. 25 (2019) Nr. 4, S. 304 - 314Online Volltext: dx.doi.org/
-
Apalutamide and overall survival in non-metastatic castration-resistant prostate cancerIn: Annals of Oncology Jg. 30 (2019) Nr. 11, S. 1813 - 1820Online Volltext: dx.doi.org/ (Open Access)
-
Circulating and tissue IMP3 levels are correlated with poor survival in renal cell carcinomaIn: International Journal of Cancer Jg. 145 (2019) Nr. 2, S. 531 - 539Online Volltext: dx.doi.org/ (Open Access)
-
Das Urachuskarzinom : Ein Update aktueller molekularer ErgebnisseIn: Der Pathologe Jg. 40 (2019) Nr. Suppl. 3, S. 239 - 243Online Volltext: dx.doi.org/
-
Die Fusionsbiopsie in der Primärdiagnostik des Prostatakarzinoms : Durchführung, Nutzen und klinische AspekteIn: Der Urologe Jg. 58 (2019) Nr. 5, S. 504 - 510Online Volltext: dx.doi.org/
-
Efficacy of apalutamide (APA) plus ongoing androgen deprivation therapy (ADT) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) and baseline (BL) comorbidities (CM)In: Journal of Clinical Oncology (JCO) Jg. 37 (2019) Nr. 15_Suppl, S. 5023 - 5023Online Volltext: dx.doi.org/
-
Ein neuer Androgenrezeptorantagonist : Darolutamid für Patienten mit nicht fernmetastasiertem, kastrationsresistentem ProstatakarzinomIn: Der Urologe Jg. 58 (2019) Nr. 10, S. 1217 - 1218Online Volltext: dx.doi.org/
-
Erectile Dysfunction in 45-Year-Old Heterosexual German Men and Associated Lifestyle Risk Factors and Comorbidities : Results From the German Male Sex StudyIn: Sexual Medicine Jg. 7 (2019) Nr. 1, S. 26 - 34Online Volltext: dx.doi.org/ (Open Access)
-
Factors Associated with Low Sexual Desire in 45-Year-Old Men : Findings from the German Male Sex-StudyIn: The Journal of Sexual Medicine Jg. 16 (2019) Nr. 7, S. 981 - 991Online Volltext: dx.doi.org/
-
Ga-PSMA-11 Positron Emission Tomography Detects Residual Prostate Cancer after Prostatectomy in a Multicenter Retrospective StudyIn: The Journal of Urology Jg. 202 (2019) Nr. 6, S. 1174 - 1181Online Volltext: dx.doi.org/
-
High soluble CGA levels are associated with poor survival in bladder cancerIn: Endocrine Connections Jg. 8 (2019) Nr. 5, S. 625 - 633Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Identifying molecular determinants of response to apalutamide (APA) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) in the SPARTAN trial.In: Journal of Clinical Oncology (JCO) Jg. 37 (2019) Nr. 7_Suppl, S. 42 - 42Online Volltext: dx.doi.org/
-
Molecular Imaging for Primary Staging of Prostate CancerIn: Seminars in Nuclear Medicine Jg. 49 (2019) Nr. 4, S. 271 - 279Online Volltext: dx.doi.org/
-
PROTEUS : A randomized, double-blind, placebo (PBO)-controlled, phase 3 trial of apalutamide (APA) plus androgen deprivation therapy (ADT) versus PBO plus ADT prior to radical prostatectomy (RP) in patients with localized high-risk or locally advanced prostate cancer (PC)In: Journal of Clinical Oncology (JCO) Jg. 37 (2019) Nr. 15_Suppl, S. TPS5100 - TPS5100Online Volltext: dx.doi.org/
-
PSA-Anstieg nach definitiver TherapieIn: Der Urologe Jg. 58 (2019) Nr. 5, S. 569 - 582Online Volltext: dx.doi.org/
-
Prostate-specific membrane antigen ligand positron emission tomography in men with nonmetastatic castration-resistant prostate cancerIn: Clinical Cancer Research Jg. 25 (2019) Nr. 24, S. 7448 - 7454Online Volltext: dx.doi.org/ (Open Access)
-
Psychosocial Resources and Quality of Life in Transgender Women following Gender-Affirming SurgeryIn: The Journal of Sexual Medicine Jg. 16 (2019) Nr. 10, S. 1672 - 1680Online Volltext: dx.doi.org/
-
Re: Erectile dysfunction in 45-year-old heterosexual German men and associated lifestyle risk factors and comorbidities : Results from the German Male sex studyIn: The Journal of Urology Jg. 202 (2019) Nr. 4, S. 644Online Volltext: dx.doi.org/
-
Re: Minimally Invasive Versus Abdominal Radical Hysterectomy for Cervical CancerIn: European Urology Jg. 75 (2019) Nr. 5, S. 875Online Volltext: dx.doi.org/
-
Re: Preliminary Results for Avelumab Plus Axitinib as First-Line Therapy in Patients with Advanced Clear-cell Renal-cell Carcinoma (JAVELIN Renal 100) : An Open-label, Dose-finding and Dose-expansion, Phase 1b TrialIn: European Urology Jg. 75 (2019) Nr. 4, S. 697 - 698Online Volltext: dx.doi.org/
-
Systemtherapie des metastasierten Tumors des oberen HarntraktesIn: Der Urologe Jg. 58 (2019) Nr. 1, S. 30 - 33Online Volltext: dx.doi.org/
-
Updated analysis of progression-free survival with first subsequent therapy (PFS2) and safety in the SPARTAN study of apalutamide (APA) in patients (pts) with high-risk nonmetastatic castration-resistant prostate cancer (nmCRPC).In: Journal of Clinical Oncology (JCO) Jg. 37 (2019) Nr. 7_Suppl, S. 144 - 144Online Volltext: dx.doi.org/
-
Validation of survivin and HMGA2 as biomarkers for cisplatin resistance in bladder cancerIn: Urologic Oncology: Seminars and Original Investigations Jg. 37 (2019) Nr. 11, S. 810.e7 - 810.e15Online Volltext: dx.doi.org/
-
68Ga-PSMA-11 PET/CT in prostate cancer local recurrence : impact of early images and parametric analysisIn: American Journal of Nuclear Medicine and Molecular Imaging Jg. 8 (2018) Nr. 5, S. 351 - 359(Open Access)
-
Apalutamide treatment and metastasis-free survival in prostate cancerIn: The New England Journal of Medicine Jg. 378 (2018) Nr. 15, S. 1408 - 1418Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Are there limits of robotic partial nephrectomy? : TRIFECTA outcomes of open and robotic partial nephrectomy for completely endophytic renal tumorsIn: Journal of Surgical Oncology Jg. 118 (2018) Nr. 1, S. 206 - 211Online Volltext: dx.doi.org/
-
Biomarkers in Urachal Cancer and Adenocarcinomas in the Bladder : A Comprehensive Review Supplemented by Own DataIn: Disease Markers (2018) 7308168Online Volltext: dx.doi.org/ (Open Access)
-
Circulating syndecan-1 is associated with chemotherapy-resistance in castration-resistant prostate cancerIn: Urologic Oncology: Seminars and Original Investigations Jg. 36 (2018) Nr. 6, S. 312.e9 - 312.e15Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Clinical Relevance and Suppressive Capacity of Human Myeloid-Derived Suppressor Cell SubsetsIn: Clinical Cancer Research Jg. 24 (2018) Nr. 19, S. 4834 - 4844Online Volltext: dx.doi.org/ (Open Access)
-
Concordance and Discordance of Sexual Identity, Sexual Experience, and Current Sexual Behavior in 45-Year-Old Men : Results From the German Male Sex-StudyIn: Sexual Medicine Jg. 6 (2018) Nr. 4, S. 282 - 290Online Volltext: dx.doi.org/ (Open Access)
-
Correlation between genomic index lesions and mpMRI and ⁶⁸Ga-PSMA-PET/CT imaging features in primary prostate cancerIn: Scientific Reports Jg. 8 (2018) Nr. 1, S. 16708Online Volltext: dx.doi.org/ (Open Access)
-
Discordant prostate specific antigen test results despite WHO assay standardizationIn: The International Journal of Biological Markers (IJBM) Jg. 33 (2018) Nr. 3, S. 275 - 282Online Volltext: dx.doi.org/ (Open Access)
-
Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer : an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trialIn: The Lancet Oncology Jg. 19 (2018) Nr. 10, S. 1404 - 1416Online Volltext: dx.doi.org/; Online Volltext: dx.doi.org/ (Open Access)
-
Fluorescence-supported lymphography and extended pelvic lymph node dissection in robot-assisted radical prostatectomy : a prospective, randomized trialIn: World Journal of Urology Jg. 36 (2018) Nr. 11, S. 1817 - 1823Online Volltext: dx.doi.org/
-
Genomic features of renal cell carcinoma with venous tumor thrombusIn: Scientific Reports Jg. 8 (2018) Nr. 1, S. 7477Online Volltext: dx.doi.org/ (Open Access)
-
Impact of long-term androgen deprivation therapy on PSMA ligand PET/CT in patients with castration-sensitive prostate cancerIn: European Journal of Nuclear Medicine and Molecular Imaging Jg. 45 (2018) Nr. 12, S. 2045 - 2054Online Volltext: dx.doi.org/ (Open Access)
-
MRI-targeted or standard biopsy for prostate-cancer diagnosisIn: The New England Journal of Medicine Jg. 378 (2018) Nr. 19, S. 1767 - 1777Online Volltext: dx.doi.org/ (Open Access)
-
Matching-adjusted indirect comparison of the effiacy of apalutamide and enzalutamide in the treatment of non-metastatic castration-resistant prostate cancerIn: Value in Health Jg. 21 (2018) Nr. Suppl. 3, S. 20 - S21Online Volltext: dx.doi.org/ (Open Access)
-
Matrix metalloproteinase 7, soluble Fas and Fas ligand serum levels for predicting docetaxel resistance and survival in castration-resistant prostate cancerIn: BJU International (BJUI) Jg. 122 (2018) Nr. 4, S. 695 - 704Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Multicentre evaluation of magnetic resonance imaging supported transperineal prostate biopsy in biopsy-naïve men with suspicion of prostate cancerIn: BJU International (BJUI) Jg. 122 (2018) Nr. 1, S. 40 - 49Online Volltext: dx.doi.org/ (Open Access)
-
Multiparametric MRI fusion-guided biopsy for the diagnosis of prostate cancerIn: Current Opinion in Urology Jg. 28 (2018) Nr. 2, S. 172 - 177Online Volltext: dx.doi.org/
-
Neue Therapieoption : Apalutamid beim nicht fernmetastasierten kastrationsresistenten ProstatakarzinomIn: Der Urologe Jg. 57 (2018) Nr. 6, S. 729 - 730Online Volltext: dx.doi.org/
-
PSMA-11–Derived dual-Labeled PSMA inhibitors for preoperative PET imaging and precise fluorescence-Guided surgery of prostate cancerIn: Journal of Nuclear Medicine (JNM) Jg. 59 (2018) Nr. 4, S. 639 - 645Online Volltext: dx.doi.org/ (Open Access)
-
Paradigmenwechsel in der Urologie : Prostatakrebsdiagnostik mittels MRT-gezielter oder konventioneller transrektaler ultraschallgesteuerter BiopsieIn: Der Urologe Jg. 57 (2018) Nr. 6, S. 727 - 728Online Volltext: dx.doi.org/
-
Pathogenic and targetable genetic alterations in 70 urachal adenocarcinomasIn: International Journal of Cancer Jg. 143 (2018) Nr. 7, S. 1764 - 1773Online Volltext: dx.doi.org/ (Open Access)
-
Prospective Multicenter Phase II Study on Focal Therapy (Hemiablation) of the Prostate with High Intensity Focused UltrasoundIn: The Journal of Urology Jg. 199 (2018) Nr. 4, S. 983 - 989Online Volltext: dx.doi.org/
-
Prospective comparison of transperineal magnetic resonance imaging/ultrasonography fusion biopsy and transrectal systematic biopsy in biopsy-naïve patientsIn: BJOG: formerly: The Journal of Obstetrics and Gynaecology of the British Commonwealth / of the British Empire; British Journal of Obstetrics and Gynaecology Jg. 121 (2018) Nr. 1, S. 53 - 60Online Volltext: dx.doi.org/ (Open Access)
-
Prostate cancer molecular imaging standardized evaluation (PROMISE) : Proposed miTNM classification for the interpretation of PSMA-ligand PET/CTIn: Journal of Nuclear Medicine (JNM) Jg. 59 (2018) Nr. 3, S. 469 - 478Online Volltext: dx.doi.org/ (Open Access)
-
Sexuality after Male-to-Female Gender Affirmation SurgeryIn: BioMed Research International (2018) 9037979Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
The Role of YKL-40 in Predicting Resistance to Docetaxel Chemotherapy in Prostate CancerIn: Urologia Internationalis Jg. 101 (2018) Nr. 1, S. 65 - 73Online Volltext: dx.doi.org/
-
⁶⁸Ga-PSMA PET/CT in the evaluation of bone metastases in prostate cancerIn: European Journal of Nuclear Medicine and Molecular Imaging Jg. 45 (2018) Nr. 6, S. 904 - 912Online Volltext: dx.doi.org/
-
68Ga-PSMA PET/CT and Volumetric Morphology of PET-Positive Lymph Nodes Stratified by Tumor Differentiation of Prostate CancerIn: Journal of Nuclear Medicine (JNM) Jg. 58 (2017) Nr. 12, S. 1949 - 1955Online Volltext: dx.doi.org/
-
Combined Clinical Parameters and Multiparametric Magnetic Resonance Imaging for Advanced Risk Modeling of Prostate Cancer : Patient-tailored Risk Stratification Can Reduce Unnecessary BiopsiesIn: European Urology Jg. 72 (2017) Nr. 6, S. 888 - 896Online Volltext: dx.doi.org/
-
Cyclin K dependent regulation of Aurora B affects apoptosis and proliferation by induction of mitotic catastrophe in prostate cancerIn: International Journal of Cancer Jg. 141 (2017) Nr. 8, S. 1643 - 1653Online Volltext: dx.doi.org/
-
Fokale Therapie des ProstatakarzinomsIn: Der Urologe Jg. 56 (2017) Nr. 10, S. 1335 - 1346Online Volltext: dx.doi.org/
-
Intraindividual Comparison of18F-PSMA-1007 PET/CT, Multiparametric MRI, and Radical Prostatectomy Specimens in Patients with Primary Prostate Cancer : A Retrospective, Proof-of-Concept StudyIn: Journal of Nuclear Medicine (JNM) Jg. 58 (2017) S. 1805 - 1810Online Volltext: dx.doi.org/
-
Investigation of the halo-artifact in 68Ga-PSMA-11-PET/MRIIn: PLoS ONE Jg. 12 (2017) Nr. 8, S. e0183329Online Volltext: dx.doi.org/ (Open Access)
-
Multiparametric-MRI-guided biopsy in the era of precision medicineIn: Archivos Espanoles de Urologia Jg. 70 (2017) Nr. 10, S. 833 - 844
-
Post-prostatectomy radiotherapy adversely affects urinary continence irrespective of radiotherapy regimeIn: World Journal of Urology Jg. 35 (2017) Nr. 12, S. 1841 - 1847Online Volltext: dx.doi.org/
-
Re: Diagnostic Accuracy of Ga-68-HBED-CC-PSMA-ligand-PET/CT Before Salvage Lymph Node Dissection for Recurrent Prostate CancerIn: European Urology Jg. 72 (2017) Nr. 3, S. 470 - 471Online Volltext: dx.doi.org/
-
The Value of PSA Density in Combination with PI-RADS™ for the Accuracy of Prostate Cancer PredictionIn: The Journal of Urology Jg. 198 (2017) Nr. 3, S. 575 - 582Online Volltext: dx.doi.org/
-
Therapy assessment in prostate cancer using choline and PSMA PET/CTIn: European Journal of Nuclear Medicine and Molecular Imaging Jg. 44 (2017) Nr. Suppl. 1, S. S78 - S83Online Volltext: dx.doi.org/
-
Transperineal vs. transrectal biopsy in MRI targetingIn: Translational Andrology and Urology Jg. 6 (2017) Nr. 3, S. 368 - 375Online Volltext: dx.doi.org/ (Open Access)
-
Re: Assessment of ⁶⁸Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer : A Prospective Single-Arm Clinical TrialIn: European Urology Jg. 76 (2019) Nr. 4, S. 538 - 539Online Volltext: dx.doi.org/
-
A New Chapter in Neoadjuvant Therapy for High-risk Prostate Cancer?In: European Urology Jg. 85 (2024) Nr. 3, S. 227 - 228Online Volltext: dx.doi.org/
-
Prostate-specific Membrane Antigen (PSMA) Spatial Biomarker : Standardized Positron Emission Tomography Disease Maps Provide Accurate Prediction of Overall Survival in Prostate CancerIn: European Urology (2024) in pressOnline Volltext: dx.doi.org/
-
The novel PROMISE framework for PSMA-PET reporting : Ready for the clinical routine?In: Clinical and Translational Imaging Jg. 12 (2024) Nr. 1, S. 1 - 3Online Volltext: dx.doi.org/ (Open Access)
-
Das metastasierte kastrationsresistente Prostatakarzinom : praxisrelevante Hilfestellungen für individuelle TherapieentscheidungenIn: Die Urologie Jg. 62 (2023) Nr. 12, S. 1267 - 1268Online Volltext: dx.doi.org/
-
Aktuelle Bildgebung für Urologen : Moderne Diagnostik in Praxis und KlinikIn: Der Urologe Jg. 61 (2022) Nr. 4, S. 355 - 356Online Volltext: dx.doi.org/ (Open Access)
-
Oligometastasierte und lokal fortgeschrittene urologische Tumoren : Moderne Diagnostik vor individualisierter multimodaler TherapieIn: Der Urologe Jg. 60 (2021) Nr. 12, S. 1525 - 1526Online Volltext: dx.doi.org/ (Open Access)
-
COVID-19 research : promising tracks leading to uro-oncologyIn: International Urology and Nephrology Jg. 52 (2020) Nr. 6, S. 995 - 997Online Volltext: dx.doi.org/ (Open Access)
-
Influence of androgen deprivation therapy on PSMA expression and PSMA-ligand PET imaging of prostate cancer patientsIn: European Journal of Nuclear Medicine and Molecular Imaging Jg. 47 (2020) Nr. 1, S. 9 - 15Online Volltext: dx.doi.org/ (Open Access)
-
Proposal for Systemic-Therapy Response-Assessment Criteria at the Time of PSMA PET/CT Imaging : The PSMA PET Progression CriteriaIn: Journal of Nuclear Medicine (JNM) Jg. 61 (2020) Nr. 5, S. 678 - 682Online Volltext: dx.doi.org/ (Open Access)
-
Therapie des oligo- und polytopmetastasierten ProstatakarzinomsIn: Der Urologe Jg. 59 (2020) Nr. 6, S. 657 - 658Online Volltext: dx.doi.org/ (Open Access)
-
Management des lokal begrenzten ProstatakarzinomsIn: Der Urologe Jg. 58 (2019) Nr. 5, S. 485Online Volltext: dx.doi.org/ (Open Access)
-
Why targeting of PSMA is a valuable adDition to the management of castration-resistant prostate cancer : The urologist's point of viewIn: Journal of Nuclear Medicine (JNM) Jg. 58 (2017) Nr. 8, S. 1207 - 1209Online Volltext: dx.doi.org/
-
Prognostic PSMA-PET PROMISE nomograms for patients with prostate cancerIn: Journal of Clinical Oncology (JCO) Jg. 42 (2024) Nr. Suppl. 16, 5016Online Volltext: dx.doi.org/
-
Subgroup analysis of real-world efficacy of enfortumab vedotin in patients with metastatic/locally advanced urothelial carcinoma from a European databaseIn: Journal of Clinical Oncology (JCO) Jg. 42 (2024) Nr. Suppl. 16, e16562Online Volltext: dx.doi.org/ (Open Access)
-
Updated results on the bispecific PSMAxCD3 antibody CC-1 for treatment of prostate cancerIn: Journal of Clinical Oncology (JCO) Jg. 42 (2024) Nr. Suppl. 16, 2536Online Volltext: dx.doi.org/ (Open Access)
-
Analysing the Tumour Transcriptome of Prostate Cancer to Predict Efficacy of Lu-PSMA Therapy
Annual Congress of the European Association of Nuclear Medicine, 9-13 September 2023 Vienna, Austria,In: European Journal of Nuclear Medicine and Molecular Imaging Jg. 50 (2023) Nr. 1 supplement, S. S180Online Volltext: dx.doi.org/ (Open Access) -
Assessment of Response Evaluation Criteria in PSMA PET/CT (RECIP 1.0) in Metastatic Castration-Resistant Prostate Cancer
Annual Congress of the European Association of Nuclear Medicine, 9-13 September 2023 Vienna, Austria,In: European Journal of Nuclear Medicine and Molecular Imaging Jg. 50 (2023) Nr. 1 supplement, S. S544 - S545Online Volltext: dx.doi.org/ (Open Access) -
Clinical development of the bispecific PSMAxCD3 antibody CC-1 for treatment of prostate cancer
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie ; 13. bis 16. Oktober 2023, Hamburg, Germany,In: Oncology Research and Treatment Jg. 46 (2023) Nr. Supplement 5: DGHO Abstracts, S. 112Online Volltext: dx.doi.org/ (Open Access) -
Improving radical prostatectomy with intraoperative ex-vivo PSMA-PET/CT imaging
Annual Congress of the European Association of Nuclear Medicine, 9-13 September 2023 Vienna, Austria,In: European Journal of Nuclear Medicine and Molecular Imaging Jg. 50 (2023) Nr. 1 supplement, S. S586Online Volltext: dx.doi.org/ (Open Access) -
Inter-institutional differences and common ground in 177Lu-PSMA radionuclide therapy : International survey in 95 theranostic centersIn: European Journal of Nuclear Medicine and Molecular Imaging Jg. 50 (2023) Nr. Suppl. 1, S. S92Online Volltext: dx.doi.org/ (Open Access)
-
Inter-institutional differences and common ground in 177Lu-PSMA radionuclide therapy : International survey in 95 theranostic centers
55th Annual Conference of the Society-of-Nuclear-Medicine (SNMICON); NOV 16-19, 2023; Jodhpur, India,In: Journal of Nuclear Medicine (JNM) Jg. 64 (2023) Nr. Suppl. 1, P843 -
Intraoperative microPET/CT imaging for PSMA-positive cancer foci in radical prostatectomy – feasibility study
38th Annual EAU (European Association of Urology) Congress ; EAU23 ; 10 - 13 March 2023, Milan, Italy,In: European Urology Jg. 83 (2023) Nr. Supplement 1, S. S687Online Volltext: dx.doi.org/ -
Molecular analysis of urothelial carcinoma to predict the efficacy of immune checkpoint inhibitor therapy
38th Annual European Association of Urology Congress (EAU) ; March 10 - 13, 2023, Milan, Italy,In: European Urology Jg. 83 (2023) Nr. Supplement 1: Abstracts EAU23, S. S1679 - S1680Online Volltext: dx.doi.org/ -
Online-adaptive Strahlentherapie beim muskelinvasiven Blasenkarzinom mit angepassten PTVSäumen : Vorteil gegenüber der IGRT zum Zeitpunkt der Adaptation und gute akkumulierte EUD zum Zeitpunkt der ApplikationIn: Strahlentherapie und Onkologie: Journal of Radiation Oncology, Biology, Physics Jg. 199 (2023) Nr. Suppl. 1, S. S153Online Volltext: dx.doi.org/
-
Performance Evaluation of 18F-PSMA and 68Ga-PSMA in a Novel MicroPET/CT System Dedicated to Radioguided Surgery
Annual Congress of the European Association of Nuclear Medicine, 9-13 September 2023, Vienna, Austria,In: European Journal of Nuclear Medicine and Molecular Imaging Jg. 50 (2023) Nr. 1 supplement, S. S131Online Volltext: dx.doi.org/ (Open Access) -
Practical RECIP : Visual assessment of Response Evaluation Criteria In PSMA-PET/CT in metastatic castration-resistant prostate cancer
55th Annual Conference of the Society-of-Nuclear-Medicine (SNMICON); NOV 16-19, 2023; Jodhpur, India,In: Journal of Nuclear Medicine (JNM) Jg. 64 (2023) Nr. Suppl. 1, P1619 -
Prostate Cancer Molecular Imaging Standardized Evaluation : The PROMISE V2 Framework Including Response Evaluation for Clinical TrialsIn: Strahlentherapie und Onkologie: Journal of Radiation Oncology, Biology, Physics Jg. 199 (2023) Nr. Suppl. 1, S. S150Online Volltext: dx.doi.org/ (Open Access)
-
Surgical safety and quality of radical cystectomy and pelvic lymph node dissection after neoadjuvant Durvalumab and Cisplatin/Gemcitabine for muscle invasive bladder cancer : Results from the SAKK 06/17 phase II study
38th Annual EAU (European Association of Urology) Congress ; EAU23 ; 10 - 13 March 2023, Milan, Italy,In: European Urology Jg. 83 (2023) Nr. Supplement 1, S. S230 - S231Online Volltext: dx.doi.org/ -
The Updated Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE V2.0) Framework for Standardized Reporting of PSMA-PET
Annual Congress of the European Association of Nuclear Medicine, 19-13 September 2023, Vienna, Austria,In: European Journal of Nuclear Medicine and Molecular Imaging Jg. 50 (2023) Nr. 1 supplement, S. S177Online Volltext: dx.doi.org/ (Open Access) -
Enfortumab Vedotin bei metastasiertem Urothelkarzinom : retrospektive, multizentrische Patientenkohorte
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 7.–10. Oktober 2022, Wien, Austria,In: Oncology Research and Treatment Jg. 45 (2022) Nr. Supplement 2, S. 64Online Volltext: dx.doi.org/ (Open Access) -
Enfortumab vedotin in metastatic urothelial carcinoma : Retrospective multicentre patient cohort
Annual Meeting of the European-Society-for-Medical-Oncology (ESMO): SEP 09-13, 2022; Paris, France,In: Annals of Oncology Jg. 33 (2022) Nr. Suppl. 7: Abstract Book of the ESMO Congress 2022, 9 - 13 September 2022, S. S1342Online Volltext: dx.doi.org/ (Open Access) -
FAPI, PSMA and FDG PET/CT in patients with advanced metastatic castration-resistant prostate cancer (mCRPC) : a triple tracer comparison
EANM‘22 ; 35th Annual Congress of the European Association of Nuclear Medicine October ; 15-19, 2022 Barcelona, Spain,In: European Journal of Nuclear Medicine and Molecular Imaging Jg. 49 (2022) Nr. Supplement 1, S. S118 - S119Online Volltext: dx.doi.org/ (Open Access) -
Impact of surgical experience prior to robot-assisted partial nephrectomy on surgical outcomes : Large multicenter analysis with 2,500 patients
EAU22: 37th Annual EAU Congress, 01.-04.07.2022, Amsterdam,In: European Urology Jg. 81 (2022) Nr. Supplement 1: Abstracts EAU22 - 37th Annual EAU Congress, S. S191 - S192Online Volltext: dx.doi.org/ -
Novel framework for treatment response evaluation using PSMA-PET/CT in patients with metastatic castration-resistant prostate cancer (RECIP 1.0) : an international multicenter study
EANM‘22 ; 35th Annual Congress of the European Association of Nuclear Medicine ; October 15-19, 2022 Barcelona, Spain,In: European Journal of Nuclear Medicine and Molecular Imaging Jg. 49 (2022) Nr. Supplement 1, S. S269Online Volltext: dx.doi.org/ (Open Access) -
Novel framework for treatment response evaluation using PSMA-PET/CT in patients with metastatic castration-resistant prostate cancer (RECIP 1.0) : An international multicenter study
EAU22: 37th Annual EAU Congress, 01.-04.07.2022, Amsterdam,In: European Urology Jg. 81 (2022) Nr. Supplement 1: Abstracts EAU22 - 37th Annual EAU Congress, S. S794 - S795Online Volltext: dx.doi.org/ -
Novel framework for treatment response evaluation using PSMA-PET/CT in patients with metastatic castration-resistant prostate cancer (RECIP 1.0) : an international multicenter study
2022 ASCO Genitourinary Cancers Symposium, 17.-19.02.2022, San Fransisco,In: Journal of Nuclear Medicine (JNM) Jg. 40 (2022) Nr. 6, Supplement: 2022 ASCO Genitourinary Cancers Symposium, jnumed.121.263072Online Volltext: dx.doi.org/ (Open Access) -
Novel framework for treatment response evaluation using PSMA-PET/CT in patients with metastatic castration-resistant prostate cancer (RECIP) : An international multicenter studyIn: Journal of Clinical Oncology (JCO) Jg. 40 (2022) Nr. Suppl. 6, 42Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
PROTEUS: A randomized, double-blind, placebo (PBO)-controlled, phase 3 trial of apalutamide (APA) plus androgen deprivation therapy (ADT) versus PBO plus ADT prior to radical prostatectomy (RP) in patients (pts) with localized or locally advanced high-risk prostate cancer (PC)In: Journal of Clinical Oncology (JCO) (2022) TPS285Online Volltext: dx.doi.org/ (Open Access)
-
Perioperative chemoimmunotherapy with durvalumab for operable muscle-invasive urothelial carcinoma (MIUC) : Primary analysis of the single arm phase II trial SAKK 06/17In: Journal of Clinical Oncology (JCO) Jg. 40 (2022) Nr. 16_Suppl., S. 4515Online Volltext: dx.doi.org/ (Open Access)
-
Profil der multizentrischen Kohorte der Klinischen Kommunicationsplattform des Deutschen Konsortiums für Translationale Krebsforschung (DKTK)
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 7.–10. Oktober 2022, Wien, Austria,In: Oncology Research and Treatment Jg. 45 (2022) Nr. Supplement 2, S. 13Online Volltext: dx.doi.org/ (Open Access) -
Risk of adverse outcomes after prostatectomy in patients diagnosed with IUSP <= 2 prostate cancer on MRI/TRUS fusion biopsy
EAU22: 37th Annual EAU Congress, 01.-04.07.2022, Amsterdam,In: European Urology Jg. 81 (2022) Nr. Supplement 1: Abstracts EAU22 - 37th Annual EAU Congress, S. S438Online Volltext: dx.doi.org/ -
Robot-assisted partial nephrectomy for multiple renal tumors : a multicenter analysis
EAU22: 37th Annual EAU Congress, 01.-04.07.2022, Amsterdam,In: European Urology Jg. 81 (2022) Nr. Supplement 1: Abstracts EAU22 - 37th Annual EAU Congress, S. S543Online Volltext: dx.doi.org/ -
Target Expression and FAP-Directed Tumour Imaging in a Large, Single-Centre PET Database of 324 Patients and 21 Tumour Entities
EANM‘22 ; 35th Annual Congress of the European Association of Nuclear Medicine ; October 15-19, 2022, Barcelona, Spain,In: European Journal of Nuclear Medicine and Molecular Imaging Jg. 49 (2022) Nr. Supplement 1, S. S119 - S120Online Volltext: dx.doi.org/ (Open Access) -
Urogenitale Sarkome im Erwachsenenalter : eine populationsbasierte Analyse von Tumorcharakteristika, Inzidenz und Überleben in Nordrhein-Westfalen (NRW)
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 7.–10. Oktober 2022, Wien, Austria,In: Oncology Research and Treatment Jg. 45 (2022) Nr. Supplement 2, S. 63Online Volltext: dx.doi.org/ (Open Access) -
Detection of significant prostate cancer using target saturation in transperineal magnetic resonance imaging/transrectal ultrasonography-fusion biopsy : A prospective, randomized comparison to conventional target biopsyIn: European Urology Jg. 79 (2021) Nr. Suppl. 1, 4460
-
Development of a novel framework for treatment response evaluation using PSMA-PET/CT in patients with metastatic castration-resistant prostate cancer (RECIP) : An international multicenter study
EANM‘21 ; 34th Annual Congress of the European Association of Nuclear Medicine ; October 20-23, 2021, Virtual,In: European Journal of Nuclear Medicine and Molecular Imaging Jg. 48 (2021) Nr. Suppl. 1, S. S311 - S312Online Volltext: dx.doi.org/ (Open Access) -
FDG-PET avidity as a prognostic biomarker for overall survival in renal cell carcinoma
2021 ASCO Annual Meeting, 4. - 8. June 2021, virtuell,In: Journal of Clinical Oncology (JCO) Jg. 39 (2021) Nr. Suppl. 15, S. e16564Online Volltext: dx.doi.org/ (Open Access) -
Ga-68-versus F-18-PSMA for Cerenkov Luminescence and autoradiography in a prostate cancer mouse modelIn: European Journal of Nuclear Medicine and Molecular Imaging Jg. 48 (2021) Nr. Suppl. 1, S. 17
-
Initial experience from a multicentre clinical trial evaluating the safety and performance of a drop-in gamma probe for sentinel lymph node biopsy in prostate cancerIn: European Journal of Nuclear Medicine and Molecular Imaging Jg. 48 (2021) Nr. Suppl. 1, S. 554
-
Interim PSMA PET/CT for response evaluation during LuPSMA treatment in mCRPC (INTERIM PET) : An explorative, multicenter studyIn: Journal of Clinical Oncology (JCO) Jg. 39 (2021) Nr. 15_Suppl, S. 5066 - 5066Online Volltext: dx.doi.org/
-
Nomograms to predict outcome after LuPSMA radionuclide therapy in men with metastatic castration-resistant prostate cancer : An international multicenter retrospective studyIn: European Journal of Nuclear Medicine and Molecular Imaging Jg. 48 (2021) Nr. Suppl. 1, S. 63 - S64
-
PRIMORDIUM : A randomized, international, trial-in-progress of adding apalutamide to radiotherapy and an LHRH agonist in high-risk patients with PSMA-PET-positive hormone-sensitive prostate cancerIn: Annals of Oncology Jg. 32 (2021) Nr. Suppl. 5, S. 676 - S677Online Volltext: dx.doi.org/ (Open Access)
-
Phase 3 multicenter randomized trial of PSMA PET/CT prior to definitive radiation therapy for unfavorable intermediate-risk or high-risk prostate cancer [PSMA dRT] : Study ProtocolIn: Cancer Research Jg. 81 (2021) Nr. 13, CT257
-
Phase III randomized trial of PSMA PET prior to definitive radiation therapy for unfavorable intermediate-risk or high-risk prostate cancer [PSMA dRT] : Study protocol NCT04457245
2021 Genitourinary Cancers Symposium, 11 - 13 Feb 2021, online,In: Journal of Clinical Oncology (JCO) Jg. 39 (2021) Nr. 6, Supplement, S. TPS172Online Volltext: dx.doi.org/ (Open Access) -
The SENSEI laparoscopic tethered gamma probe for sentinel lymph node biopsy in prostate cancer : Initial experience from a multicenter clinical trialIn: Journal of Nuclear Medicine (JNM) Jg. 62 (2021) Nr. Suppl. 1, 899
-
Final survival results from SPARTAN, a phase III study of apalutamide (APA) versus placebo (PBO) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC)In: Journal of Clinical Oncology (JCO) Jg. 38 (2020) Nr. 15_Suppl., S. 5516Online Volltext: dx.doi.org/
-
Health-related quality of life (HRQoL) at final analysis of the SPARTAN study of apalutamide (APA) vs placebo (PBO) in patients (pts) with non-metastatic castration-resistant prostate cancer (nmCRPC) receiving androgen deprivation therapy (ADT)In: Annals of Oncology Jg. 31 (2020) Nr. Suppl. 4, S. S521Online Volltext: dx.doi.org/ (Open Access)
-
Mapping prostate cancer lesions pre/post unsuccessful salvage lymph node dissection employing PSMA-PETIn: Journal of Nuclear Medicine (JNM) Jg. 61 (2020) Nr. Suppl. 1, S. 1270
-
Molecular determinants of prostate specific antigen (PSA) kinetics and clinical response to apalutamide (APA) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) in SPARTANIn: Journal of Clinical Oncology (JCO) Jg. 38 (2020) Nr. 15_Suppl.,
-
PSMA-PET identifies PCWG3 target populations with high concordance however superior reproducibility when compared to conventional imagingIn: Journal of Nuclear Medicine (JNM) Jg. 61 (2020) Nr. Suppl. 1, S. 1260
-
Patient-reported sexual and urinary function in nonmetastatic castration-resistant prostate cancer (nmCRPC) when treated with apalutamide (APA) vs placebo (PBO) and ongoing androgen deprivation therapy (ADT) in SPARTAN
ESMO Asia Virtual Congress 2020 ; 20-22 November 2020,In: Annals of Oncology Jg. 31 (2020) Nr. Supplement 6, S. S1327Online Volltext: dx.doi.org/ (Open Access) -
Preliminary Investigations on Radiation Exposure in [68Ga]Ga-PSMA-11 based Cerenkov Luminescence Imaging Procedures
EANM‘20 ; Annual Congress of the European Association of Nuclear Medicine ; October 22 – 30, 2020, Wien, Virtual,In: European Journal of Nuclear Medicine and Molecular Imaging Jg. 47 (2020) Nr. Supplement 1, S. S212Online Volltext: dx.doi.org/ (Open Access) -
Abstract CT129: (APA) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) in the SPARTAN studyIn: Cancer Research Jg. 79 (2019) Nr. Suppl. 13,Online Volltext: dx.doi.org/
-
Age-related efficacy and safety of apalutamide (APA) plus ongoing androgen deprivation therapy (ADT) in subgroups of patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC): Post hoc analysis of SPARTANIn: Journal of Clinical Oncology (JCO) Jg. 37 (2019) Nr. 15, S. 5024 - 5024Online Volltext: dx.doi.org/ (Open Access)
-
Predictors of falls and fractures in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) treated with apalutamide (APA) plus ongoing androgen deprivation therapy (ADT)In: Journal of Clinical Oncology (JCO) Jg. 37 (2019) Nr. 15, S. 5025 - 5025Online Volltext: dx.doi.org/ (Open Access)
-
Health-related quality of life (HRQoL) after progressive disease (PD) in SPARTAN : A phase III trial of apalutamide (APA) versus placebo (PBO) in men with nonmetastatic castration-resistant prostate cancer (nmCRPC)In: Annals of Oncology Jg. 29 (2018) Nr. Suppl. 8, S. viii276 - viii277Online Volltext: dx.doi.org/ (Open Access)
-
Impact of intervening in high-risk nonmetastatic castration-resistant prostate cancer (HRnmCRPC) on metastatic castration-resistant prostate cancer (mCRPC) disease burdenIn: Journal of Clinical Oncology (JCO) Jg. 36 (2018) Nr. Suppl. 15, S. e17010 - e17010Online Volltext: dx.doi.org/ (Open Access)
-
Impact of long-term androgen deprivation therapy on PSMA-ligand PET/CT in patients with castration sensitive prostate cancerIn: European Journal of Nuclear Medicine and Molecular Imaging Jg. 45 (2018) Nr. Suppl. 1, S. 22 - S23Online Volltext: dx.doi.org/ (Open Access)
-
Potentially Targetable Molecular Alterations in 70 Cases of Urachal Cancer
Geared to Learn ; USCAP 107th Annual Meeting ; March 17–23, 2018, Vancouver,In: Modern Pathology Jg. 31 (2018) Nr. Suppl. 2, S. 378Online Volltext: dx.doi.org/ (Open Access) -
Predicting disease progression in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) : An analysis from the phase 3 SPARTAN trialIn: Journal of Clinical Oncology (JCO) Jg. 36 (2018) Nr. Suppl. 15, S. 5034 - 5034Online Volltext: dx.doi.org/ (Open Access)
-
Relationship of time to metastasis (TTM) and site of metastases in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) : Results from the phase 3 SPARTAN trialIn: Journal of Clinical Oncology (JCO) Jg. 36 (2018) Nr. Suppl. 15, S. 5033 - 5033Online Volltext: dx.doi.org/ (Open Access)
-
SPARTAN, a phase 3 double-blind, randomized study of apalutamide (APA) versus placebo (PBO) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC)In: Journal of Clinical Oncology (JCO) Jg. 36 (2018) Nr. 6 Suppl., S. 161Online Volltext: dx.doi.org/ (Open Access)
-
SPARTAN, a phase 3 double-blind, randomized study of apalutamide versus placebo in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC)
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie ; 28. September - 2. Oktober 2018, Wien,In: Oncology Research and Treatment Jg. 41 (2018) Nr. Suppl. 4, S. 43Online Volltext: dx.doi.org/ (Open Access) -
Treatment of Small Renal MassesIn: Urologic Oncology / Merseburger, Axel S.; Burger, Maximilian 2019, S. 555 - 568Online Volltext: dx.doi.org/
-
Multiparametric MRI and MRI/TRUS Fusion Guided Biopsy for the Diagnosis of Prostate CancerIn: Molecular & Diagnostic Imaging in Prostate Cancer: Clinical Applications and Treatment Strategies / Schatten, Heide (Hrsg.) 2018, S. 87 - 98Online Volltext: dx.doi.org/
-
Histotype-specic overall survival of patients with urothelial carcinoma from the largest EU cancer registry in North Rhine-Westphalia, Germany
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie ; 13. bis 16. Oktober 2023, Hamburg, Germany,In: Oncology Research and Treatment Jg. 46 (2023) Nr. Supplement 5: DGHO Abstracts, S. 321 - 322Online Volltext: dx.doi.org/ (Open Access) -
Inzidenz und Überleben von Patienten mit Urothelkarzinom in Nordrhein-Westfalen (NRW) : Analyse des Landeskrebsregister (LKR) von den Jahren 2008-2019
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 7.–10. Oktober 2022, Wien, Austria,In: Oncology Research and Treatment Jg. 45 (2022) Nr. Supplement 2, S. 318Online Volltext: dx.doi.org/ (Open Access) -
Klinische Wirksamkeit kontemporärer Systemtherapie mit Immuntherapie beim metastasierten Urothelkarzinom, eine monozentrische Evaluation
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 7.–10. Oktober 2022, Wien, Austria,In: Oncology Research and Treatment Jg. 45 (2022) Nr. Supplement 2, S. 318Online Volltext: dx.doi.org/ (Open Access)